ArticlePloS one2025
Bayesian mediation analysis using patient-reported outcomes from AI chatbots to infer causal pathways in clinical trials.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of artificial intelligence (AI) chatbots into clinical trials offers a transformative approach to collecting patient-reported outcomes (PROs). Despite the increasing use of AI chatbots for real-time, interactive data gathering, systematic frameworks for analyzing these rich datasets-especially in uncovering causal relationships-remain limited. This study addresses this gap by applying a Bayesian mediation framework to PROs collected via AI chatbot interactions, uncovering causal pathways linking treatment effects to outcomes through mediators like adverse events and patient-specific covariates. Using a simulation-based approach with GPT-4o, synthetic patient-chatbot dialogues were generated to evaluate the performance of the Bayesian mediation framework, which effectively decomposed total effects into direct and indirect components while quantifying uncertainty through credible intervals. The results demonstrated low bias (<0.05), robust coverage (>85%), in estimation of the direct, indirect effect and other variables of the mediation pathways, underscoring its potential to improve clinical trial data accuracy and depth. By integrating AI chatbot-based PRO collection with Bayesian mediation analysis, this study presents a scalable and adaptive framework for quantifying causal pathways, enhancing the quality of patient-reported data, and supporting personalized, data-driven decision-making in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.